Hartford Funds Management Co LLC Purchases New Holdings in Zoetis Inc. (NYSE:ZTS)

Hartford Funds Management Co LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,479 shares of the company’s stock, valued at approximately $292,000.

Other large investors have also recently bought and sold shares of the company. Savant Capital LLC lifted its stake in shares of Zoetis by 9.0% during the fourth quarter. Savant Capital LLC now owns 8,002 shares of the company’s stock valued at $1,579,000 after acquiring an additional 660 shares during the period. Alpha Cubed Investments LLC raised its holdings in Zoetis by 17.6% during the 4th quarter. Alpha Cubed Investments LLC now owns 118,162 shares of the company’s stock worth $23,322,000 after purchasing an additional 17,708 shares during the last quarter. MONECO Advisors LLC acquired a new position in Zoetis during the 4th quarter valued at about $200,000. Brighton Jones LLC boosted its stake in shares of Zoetis by 12.4% in the 4th quarter. Brighton Jones LLC now owns 3,127 shares of the company’s stock valued at $617,000 after purchasing an additional 344 shares during the last quarter. Finally, Mission Wealth Management LP grew its position in shares of Zoetis by 6.0% during the 4th quarter. Mission Wealth Management LP now owns 2,586 shares of the company’s stock worth $510,000 after buying an additional 147 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

ZTS traded down $0.53 during trading hours on Tuesday, hitting $159.17. 3,647,859 shares of the company’s stock were exchanged, compared to its average volume of 3,147,432. The stock has a market cap of $72.80 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 2.42 and a beta of 0.85. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The stock’s 50-day moving average is $170.66 and its two-hundred day moving average is $179.12. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm earned $1.15 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays decreased their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $216.13.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 2,209 shares of company stock worth $371,293 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.